George L. Bakris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
George L. Bakris has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Matthew R. Weir
3 shared publicationsJames R. Sowers
2 shared publicationsJay Garg
Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian/St Luke's Medical Center, Chicago, IL 60612, USA
2 shared publicationsAdrian W. Messerli
From Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian/St Luke’s Medical Center, Chicago, Ill (J.G., G.L.B.); and Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, Ohio (A.W.M.).
1 shared publicationAndrew S. Levey
1 shared publicationAndrew Tonkin
1 shared publication
Latest Publications
- Retraction
- 5 November 2009
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 30 (6) , 563
Retraction Statement
- 5 November 2009
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 30 (6) , 563
RetractionRetraction Statement
- 1 March 2005
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 19 (2) , 74-79
The rationale and design of the Glycemic Effects in Diabetes Mellitus
- 1 March 2005
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 19 (2) , 74-79
The rationale and design of the Glycemic Effects in Diabetes Mellitus
- 21 October 2003
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (16) , e114-5
Kidney Failure and Cardiovascular Disease
- 21 October 2003
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (16) , e114-5
Kidney Failure and Cardiovascular Disease
- 21 May 2003
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 5 (3) , 202-209
Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed‐Dose Combination Approaches
Data from the Third National Health and Nutrition Examination Survey (NHANES III) demonstrate that only 11% of people with diabetes who are treated for high blood pressure achieve the blood pressure goal of p=0.001). At 3 months, more participants in the combination group achieved treatment goal (63% combination vs. 37% conventional; p=0.002). Data analysis at 3 months comparing blood pressure control rates between the fixed‐dose combination group (with out HCTZ) to the conventional group (receiving HCTZ) showed an even greater disparity in blood pressure goal achievement (87% combination without HCTZ vs. 37% conventional group with HCTZ; p=0.0001). We conclude that initial therapy with a fixed‐dose combination may be more efficacious than conventional monotherapy approaches for achieving blood pressure goals in the diabetic patient. A fixed‐dose combination approach appears as safe as the current conventional approaches.
- 21 May 2003
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 5 (3) , 202-209
Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed‐Dose Combination Approaches
Data from the Third National Health and Nutrition Examination Survey (NHANES III) demonstrate that only 11% of people with diabetes who are treated for high blood pressure achieve the blood pressure goal of p=0.001). At 3 months, more participants in the combination group achieved treatment goal (63% combination vs. 37% conventional; p=0.002). Data analysis at 3 months comparing blood pressure control rates between the fixed‐dose combination group (with out HCTZ) to the conventional group (receiving HCTZ) showed an even greater disparity in blood pressure goal achievement (87% combination without HCTZ vs. 37% conventional group with HCTZ; p=0.0001). We conclude that initial therapy with a fixed‐dose combination may be more efficacious than conventional monotherapy approaches for achieving blood pressure goals in the diabetic patient. A fixed‐dose combination approach appears as safe as the current conventional approaches.
- 1 May 2003
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 113 (5) , 35-50
The evolution of treatment guidelines for diabetic nephropathy
In recent years, new drug development and late-breaking research data have put treatment guidelines for diabetic nephropathy in a state of flux. In particular, trials of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), coupled with enhanced understanding of the renin-angiotensin pathway, have influenced recommendations for patient care. Here, Dr Bakris highlights both the steadfast features and the recent refinements of treatment guidelines for diabetic nephropathy. He describes their backing in research findings and outlines practical antihypertensive and renoprotective therapies to curtail risks of nephropathy and cardiovascular disease in patients with diabetes.
- 1 May 2003
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 113 (5) , 35-50
The evolution of treatment guidelines for diabetic nephropathy
In recent years, new drug development and late-breaking research data have put treatment guidelines for diabetic nephropathy in a state of flux. In particular, trials of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), coupled with enhanced understanding of the renin-angiotensin pathway, have influenced recommendations for patient care. Here, Dr Bakris highlights both the steadfast features and the recent refinements of treatment guidelines for diabetic nephropathy. He describes their backing in research findings and outlines practical antihypertensive and renoprotective therapies to curtail risks of nephropathy and cardiovascular disease in patients with diabetes.
- 1 January 2003
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 17 (1) , 7-12
Rosiglitazone reduces urinary albumin excretion in type II diabetes
This study examines the effect of rosiglitazone on urinary albumin excretion (UAE) in patients with type II diabetes. Urinary albumin: creatinine ratio (ACR) was measured in a 52-week, open-label, cardiac safety study comparing rosiglitazone and glyburide. Patients were randomised to treatment with rosiglitazone 4 mg b.i.d. or glyburide. ACR was measured at baseline and after 28 and 52 weeks of treatment. Statistically significant reductions from baseline in ACR were observed in both treatment groups at week 28. By week 52, only the rosiglitazone group showed a significant reduction from baseline. Similar results were observed for the overall study population and for the subset of patients with baseline microalbuminuria. For patients with microalbuminuria at baseline, reductions in ACR did not correlate strongly with reductions in glycosylated haemoglobin, or fasting plasma glucose, but showed strong correlation with changes in mean 24-h systolic and diastolic blood pressure for rosiglitazone-treated patients (ACR vs mean 24-h systolic blood pressure, r=0.875; ACR vs mean 24-h diastolic blood pressure, r=0.755; P<0.05 for both). No such correlation was observed for glyburide-treated patients. In conclusion, rosiglitazone treatment was associated with a decrease in urinary albumin excretion. These findings suggest a potential beneficial effect of rosiglitazone in the treatment or prevention of renal and vascular complications of type II diabetes.
- 1 January 2003
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 17 (1) , 7-12
Rosiglitazone reduces urinary albumin excretion in type II diabetes
This study examines the effect of rosiglitazone on urinary albumin excretion (UAE) in patients with type II diabetes. Urinary albumin: creatinine ratio (ACR) was measured in a 52-week, open-label, cardiac safety study comparing rosiglitazone and glyburide. Patients were randomised to treatment with rosiglitazone 4 mg b.i.d. or glyburide. ACR was measured at baseline and after 28 and 52 weeks of treatment. Statistically significant reductions from baseline in ACR were observed in both treatment groups at week 28. By week 52, only the rosiglitazone group showed a significant reduction from baseline. Similar results were observed for the overall study population and for the subset of patients with baseline microalbuminuria. For patients with microalbuminuria at baseline, reductions in ACR did not correlate strongly with reductions in glycosylated haemoglobin, or fasting plasma glucose, but showed strong correlation with changes in mean 24-h systolic and diastolic blood pressure for rosiglitazone-treated patients (ACR vs mean 24-h systolic blood pressure, r=0.875; ACR vs mean 24-h diastolic blood pressure, r=0.755; P<0.05 for both). No such correlation was observed for glyburide-treated patients. In conclusion, rosiglitazone treatment was associated with a decrease in urinary albumin excretion. These findings suggest a potential beneficial effect of rosiglitazone in the treatment or prevention of renal and vascular complications of type II diabetes.
- Open Access
- 1 November 2002
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 4 (6) , 420-440
ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?
Although angiotensin‐converting enzyme inhibitors are frequently used as antihypertensive agents to lower blood pressure and slow progression of nephropathy in patients with type 2 diabetes, evidence of their efficacy has been drawn primarily from small trials with surrogate end points. No adequately powered, long‐term trials have tested their effects to reduce the incidence of hard end points, such as progression to end‐stage renal disease or even doubling of serum creatinine in the population of patients with nephropathy from type 2 diabetes. While the results of angiotensin‐converting enzyme inhibitor trials from nondiabetic causes and even type 1 diabetes may be extrapolated to the patient with nephropathy associated with type 2 diabetes, the hard evidence is not available. This review critically evaluates the limited evidence in support of angiotensin‐converting enzyme inhibitors as renal‐protective agents in people with type 2 diabetes.
- 1 November 2002
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 4 (6) , 420-440
Open AccessACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?
Although angiotensin‐converting enzyme inhibitors are frequently used as antihypertensive agents to lower blood pressure and slow progression of nephropathy in patients with type 2 diabetes, evidence of their efficacy has been drawn primarily from small trials with surrogate end points. No adequately powered, long‐term trials have tested their effects to reduce the incidence of hard end points, such as progression to end‐stage renal disease or even doubling of serum creatinine in the population of patients with nephropathy from type 2 diabetes. While the results of angiotensin‐converting enzyme inhibitor trials from nondiabetic causes and even type 1 diabetes may be extrapolated to the patient with nephropathy associated with type 2 diabetes, the hard evidence is not available. This review critically evaluates the limited evidence in support of angiotensin‐converting enzyme inhibitors as renal‐protective agents in people with type 2 diabetes.
- 1 October 2002
- Vol. 112 (4)
Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals.
- 1 October 2002
- Vol. 112 (4)
Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals.
- 1 October 2002
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 112 (4) , 73-84
Optimal treatment of hypertension in African Americans
Treatment of hypertension in African Americans has special challenges, including a lack of objective trial data on which to base decisions and differing benefits and responses than with other patients. However, adequate control is possible and should be the goal of treating physicians. This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies.
- 1 October 2002
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 112 (4) , 73-84
Optimal treatment of hypertension in African Americans
Treatment of hypertension in African Americans has special challenges, including a lack of objective trial data on which to base decisions and differing benefits and responses than with other patients. However, adequate control is possible and should be the goal of treating physicians. This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies.
- 28 May 2002
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (21) , 2458-2461
Evaluation and Treatment of Patients With Systemic Hypertension
- 28 May 2002
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (21) , 2458-2461
Evaluation and Treatment of Patients With Systemic Hypertension